Journal of Cardiovascular Pharmacology · 2006 · 51 citations · 25 references
MedicineCardiologyPharmacologyCell SignalingInflammationSignal TransductionAtherosclerosis PharmacotherapyCarotid Artery DiseaseCytokine BiologyInflammatory MediatorsInflammatory SignalingLipid-lowering TherapyAtherosclerosis Molecular MechanismsAtherosclerosis RiskCarotid Artery AtherosclerosisCyclooxygenase-2 PathwayMatrix Metalloproteinase ModulationPlaque InflammationProinflammatory MediatorsReceptors
Prostaglandin E2 (PGE2), the product of cyclooxygenase-2 (COX-2) and prostaglandin E synthase-1 (mPGES-1), acts through its receptors (EPs) and induces matrix metalloproteinase (MMP) expression, which may favor the instability of atherosclerotic plaques. The effect of statins on EPs expression has not been previously studied. The aim of this study was to investigate the effect of atorvastatin (ATV, 80 mg/d, for one month) on EP expression in plaques and peripheral blood mononuclear cells (PBMC) of patients with carotid atherosclerosis. In addition, we studied the mechanisms by which statins could modulate EPs expression on cultured monocytic cells (THP-1) stimulated with proinflammatory cytokines (IL-1beta and TNF-alpha). Patients treated with atorvastatin showed reduced EP-1 (14 +/- 1.8% versus 26 +/- 2%; P < 0.01), EP-3 (10 +/- 1.5% versus 26 +/- 1.5%; P < 0.05), and EP-4 expression (10 +/- 4.1% versus 26.6 +/- 4.9%; P < 0.05) in atherosclerotic plaques (immunohistochemistry), and EP-3 and EP-4 mRNA expression in PBMC (real time PCR) in relation to non-treated patients. In cultured monocytic cells, atorvastatin (10 micromol/L) reduced EP-1/-3/-4 expression, along with COX-2, mPGES-1, MMP-9, and PGE2 levels elicited by IL-1beta and TNF-alpha. Similar results were noted with aspirin (100 micromol/L), dexamethasone (1 micromol/L), and the Rho kinase inhibitors Y-27632 and fasudil (10 micromol/L both). The effect of atorvastatin was reversed by mevalonate, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate. On the whole, we have shown that atorvastatin reduces EPs expression in atherosclerotic plaques and blood mononuclear cells of patients with carotid stenosis and in cultured monocytic cells. The inhibition of EP receptors could explain, at least in part, some of the mechanisms by which statins could modulate the COX-2/mPGES-1 proinflammatory pathway and favor plaque stabilization in humans.
25
Makoto Murakami, Hiroaki Naraba, Toshihiro Tanioka et al. · Journal of Biological Chemistry · 2000 · 968 citations · Full text
Carmen Bustos, Miguel Ángel Hernández-Presa, Mónica Ortego et al. · Journal of the American College of Cardiology · 1998 · 422 citations · Full text
Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Uwe Schönbeck, Galina K. Sukhova, Pierre Graber et al. · American Journal Of Pathology · 1999 · 380 citations · Full text